Review article: Updated management of acute severe ulcerative colitis: From steroids to novel medical strategies

Acute severe ulcerative colitis (ASUC) occurs in up to 25% of patients with ulcerative colitis (UC). Therapeutic approaches have evolved during the past years with the increasing bio exposure of admitted patients and the extension of the number of approved drugs for UC. In this review, we aimed to summarize the latest evidence in short‐term and long‐term medical strategies for ASUC. In addition to general principles such as venous thromboembolism prophylaxis, screening for triggering and worsening factors and close monitoring, first‐line therapy for ASUC remains intravenous corticosteroids. In naive patients, the optimum maintenance strategy for steroid‐responding patients does not necessarily include biologics. Second‐line therapy includes infliximab or calcineurin inhibitors (CNIs) with similar short‐ and long‐term colectomy rates. Despite its pathophysiological relevance, there is insufficient evidence to promote intensified induction with infliximab. Prior treatment exposure is a cornerstone for guiding therapeutic choice of short‐ and long‐term therapies in the context of ASUC: in anti‐TNF exposed patients, CNIs may be favored as a bridge therapy to vedolizumab or ustekinumab. Third‐line salvage therapy could be a therapeutic option in selected patients referred to expert centers. Additionally, evidence is accumulating regarding the use of tofacitinib in ASUC.